These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35317832)

  • 1. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
    Yang H; Yan M; Li W; Xu L
    J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
    Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
    Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
    [No Abstract]   [Full Text] [Related]  

  • 3. Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.
    Yoshida C; Kadota K; Ibuki E; Ishikawa R; Haba R; Yajima T
    Anticancer Res; 2024 Mar; 44(3):1289-1297. PubMed ID: 38423652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
    Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
    Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer.
    Giatromanolaki A; Mitrakas A; Anestopoulos I; Kontosis A; Koukourakis IM; Pappa A; Panayiotidis MI; Koukourakis MI
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.
    Xu L; Yan M; Long J; Liu M; Yang H; Li W
    Front Oncol; 2022; 12():967982. PubMed ID: 36158683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-33/ST2 Signaling and its Correlation with Macrophage Heterogeneity and Clinicopathologic Features in Human Intrahepatic Cholangiocarcinoma.
    Yasen A; Yang Z; Feng J; Liang R; Dai T; Li K; Cai Y; Wang G
    Curr Cancer Drug Targets; 2024; 24(11):1144-1156. PubMed ID: 38299398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor clinical outcomes and immunoevasive contexture in SIRPα
    Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
    Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma.
    Koga N; Hu Q; Sakai A; Takada K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Oki E; Oda Y; Mori M
    Cancer Sci; 2021 Aug; 112(8):3018-3028. PubMed ID: 34009732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.
    Hasita H; Komohara Y; Okabe H; Masuda T; Ohnishi K; Lei XF; Beppu T; Baba H; Takeya M
    Cancer Sci; 2010 Aug; 101(8):1913-9. PubMed ID: 20545696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
    Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
    Front Immunol; 2022; 13():929339. PubMed ID: 36389667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD86
    Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Liu L; Dong L; Zhang S
    PeerJ; 2020; 8():e8458. PubMed ID: 32002338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
    Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
    Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
    Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
    Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
    J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells
    Brauneck F; Oliveira-Ferrer L; Muschhammer J; Sturmheit T; Ackermann C; Haag F; Schulze Zur Wiesch J; Ding Y; Qi M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J
    Front Immunol; 2023; 14():1250258. PubMed ID: 37876933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.